Insights Into Non-Small Cell Lung Cancer: Global Clinical Research Overview

Non-small cell lung cancer (NSCLC), which constitutes about 85% of all lung cancers, originates from larger cells lining the airways or mucus-producing cells.

This FAQ section explores NSCLC's global incidence, with Asia-Pacific leading followed by Europe, North America, and other regions. Key countries with high incidence rates include China, the United States, Japan, India, and Germany.

Since 2019, the biotech and biopharma industry has initiated over 5,000 NSCLC trials globally, with Asia-Pacific leading in both trial numbers and patient recruitment rates. Marketed drugs such as Lumakras and Tagrisso target EGFR and KRAS mutations, while promising pipeline drugs like KN046 and ivonescimab indicate advancements toward more targeted therapies.

Recent advancements in precision oncology, including targeted therapies like EGFR and ALK inhibitors, along with immunotherapies such as pembrolizumab and nivolumab, have significantly improved survival rates for NSCLC patients. However, challenges persist in overcoming resistance mechanisms and addressing tumor heterogeneity, underscoring the need for continued research into innovative treatment strategies.